Dose Ranging and Dose Frequency of LIPO-102
NCT00918814 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54
Last updated 2015-03-06
Summary
Dose Ranging and Dose Frequency of LIPO-102
Conditions
- Subcutaneous Adipose Tissue Reduction
Interventions
- DRUG
-
LIPO-102
Subcutaneous Injection
- DRUG
-
Placebo
Sponsors & Collaborators
-
Neothetics, Inc
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2010-02-28
- Completion
- 2010-02-28
Countries
- United States
Study Locations
More Related Trials
-
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
NCT02397499 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202
NCT02483533 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method
NCT01853397 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat
NCT03005717 ·Status: COMPLETED ·Phase: PHASE2
-
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
NCT01044108 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
NCT02431442 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
NCT01473953 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
NCT07184632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.
NCT02941042 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429 ·Status: COMPLETED ·Phase: PHASE2
-
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
NCT04010786 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
NCT03523273 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
NCT05760248 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
NCT02835235 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects
NCT00909766 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
NCT03041792 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat
NCT05154955 ·Status: COMPLETED ·Phase: PHASE2
-
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
NCT03661879 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
NCT05970640 ·Status: COMPLETED ·Phase: PHASE1
-
A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers
NCT00509132 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NGM313 in Obese Participants
NCT03298464 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers
NCT01515592 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
NCT02970942 ·Status: COMPLETED ·Phase: PHASE2
-
Setmelanotide in a Single Patient With Partial Lipodystrophy
NCT03262610 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of S-309309 in Obese Adults
NCT05925114 ·Status: COMPLETED ·Phase: PHASE2